Canada is shipping 800 doses of its new and experimental Ebola vaccine to the World Health Organization in Geneva for testing. The vaccine was developed at the government laboratory in Winnipeg and has shown promising results in animals. To be clear, the vaccine, if it were approved for humans, will not help those who are already ill with Ebola. And it would have to be produced in huge amounts to inoculate a vast population. It is a program that might that might take years. And this has raised some criticism. It is said that greater emphasis should be placed on an experimental diagnostic test from Britain. This, they say, has the promise to identify Ebola victims faster and thus isolate them faster. The value of this in stopping further infection is obvious. The debate goes on. Wall Street Journal
